Document is current
Any future updates will be listed below
-
Authors
Strati, Paolo http://orcid.org/0000-0002-7445-1459
Jallouk, Andrew P.
Sun, Ryan
Choi, Jaihee
Das, Kaberi http://orcid.org/0000-0003-4702-0386
Cherng, Hua-Jay
Ahmed, Sairah http://orcid.org/0000-0001-7302-8299
Lee, Hun J.
Iyer, Swaminathan P.
Nair, Ranjit
Nastoupil, Loretta J. http://orcid.org/0000-0001-6071-8610
Steiner, Raphael E. http://orcid.org/0000-0003-3717-3629
Huff, Chad D.
Yu, Yao
Mistry, Haleigh
Pulsifer, Brittany
Noorani, Mansoor
Saini, Neeraj
Shpall, Elizabeth J.
Kebriaei, Partow http://orcid.org/0000-0002-8607-9404
Flowers, Christopher R. http://orcid.org/0000-0002-9524-3990
Westin, Jason R.
Hildebrandt, Michelle A. T.
Neelapu, Sattva S. http://orcid.org/0000-0003-1045-4914
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Center for Scientific Review (P30 CA016672)
U.S. Department of Health & Human Services | NIH | Center for Information Technology (R21)
Lymphoma Research Foundation (CDA)
Shirley Stein Scientific Endowment Research Award
- License Information
-
More Information
Article History
Received: 8 February 2022
Revised: 5 September 2022
Accepted: 9 September 2022
First Online: 20 September 2022
Competing interests
: PS is a consultant or has served on advisory boards for Kite Gilead, Sobi, Roche-Genentech, Hutchinson MediPharma, ADC Therapeutics, Incyte Morphosys, and TG Therapeutics, and received research funds from Sobi, Astrazeneca-Acerta, ADC Therapeutics, and ALX Oncology. SSN has received personal fees from Kite, a Gilead Company, Merck, Bristol Myers Squibb, Novartis, Celgene, Pfizer, Allogene Therapeutics, Sellas Life Sciences, Cell Medica/Kuur/Athenex, Incyte, Precision Biosciences, Legend Biotech, Adicet Bio, Calibr, Unum Therapeutics, Bluebird Bio, and Sana Biotechnology; research support from Kite, a Gilead Company, Bristol Myers Squibb, Merck, Poseida, Cellectis, Celgene, Karus Therapeutics, Unum Therapeutics, Allogene Therapeutics, Precision Biosciences, Acerta, and Adicet Bio; royalties from Takeda Pharmaceuticals; and has intellectual property related to cell therapy.
